Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Show more

Location: 1000 Skokie Boulevard, Wilmette, IL, 60091, United States | Website: https://www.monopartx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

191.7M

52 Wk Range

$2.15 - $54.30

Previous Close

$31.34

Open

$30.90

Volume

31,768

Day Range

$30.90 - $35.90

Enterprise Value

137.1M

Cash

54.55M

Avg Qtr Burn

-2.603M

Insider Ownership

34.56%

Institutional Own.

48.65%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.